Abstract
Introduction: The incidence of type 1 diabetes (T1D) is increasing worldwide and there is a very large need for effective therapies. Essentially no therapies other than insulin are currently approved for the treatment of T1D. Drugs already in use for type 2 diabetes and many new drugs are under clinical development for T1D, including compounds with both established and new mechanisms of action.
Content of the Review: Most of the new compounds in clinical development are currently in Phase 1 and 2. Drug classes discussed in this review include new insulins, SGLT inhibitors, GLP-1 agonists, immunomodulatory drugs including autoantigens and anti-cytokines, agents that regenerate β-cells and others. Regulatory Considerations: In addition, considerations are provided with regard to the regulatory environment for the clinical development of drugs for T1D, with a focus on the United States Food and Drug Administration and the European Medicines Agency. Future opportunities, such as combination treatments of immunomodulatory and beta-cell regenerating therapies, are also discussed.Keywords: Type 1 diabetes, new drug development, regulatory environment, FDA, EMA, new mechanisms of action, insulins; anti-inflammatory drugs, immunomodulatory, islet regeneration.
Related Journals
Endocrine, Metabolic & Immune Disorders - Drug Targets
Related Books
Epidemiology of Type 2 Diabetes
Frontiers in Clinical Drug Research-Diabetes and Obesity
Frontiers in Clinical Drug Research-Diabetes and Obesity
Frontiers in Clinical Drug Research-Diabetes and Obesity
Frontiers in Clinical Drug Research-Diabetes and Obesity
Frontiers in Clinical Drug Research-Diabetes and Obesity
Frontiers in Clinical Drug Research-Diabetes and Obesity
Hypercalcemia Pathophysiology & Treatment
Microcirculation and Insulin Resistance
Obesity and Disease in an Interconnected World: A Systems Approach to Turn Huge Challenges into Amazing Opportunities
104
4